# Healthpeak Properties, Inc.: overview

DOC · NYSE · CIK 765880 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/doc.md) · [Financials](/companies/doc/financials.md) · [Filings](/companies/doc/filings.md) · [Insiders](/companies/doc/insiders.md)

Latest reported revenue: [$216.5m](/filings/0001628280-26-053373.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053373).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [143](/filings/0001628280-25-046273.md) | [146 d](/filings/0001628280-26-005044.md) | [149](/filings/0001628280-26-031287.md) | [149](/filings/0001628280-26-053373.md) | [150](/filings/0001628280-25-046273.md) | [156 d](/filings/0001628280-26-005044.md) | [200](/filings/0001628280-26-031287.md) | [216](/filings/0001628280-26-053373.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [60.1%](/filings/0001628280-25-046273.md) | [3.1% d](/filings/0001628280-26-005044.md) | [28.8%](/filings/0001628280-26-031287.md) | [21.3%](/filings/0001628280-26-053373.md) | [(77.8%)](/filings/0001628280-25-046273.md) | [73.2% d](/filings/0001628280-26-005044.md) | [96.6%](/filings/0001628280-26-031287.md) | [24.4%](/filings/0001628280-26-053373.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001628280-25-046273.md) | not reported | [0.06](/filings/0001628280-26-031287.md) | [0.05](/filings/0001628280-26-053373.md) | [(0.17)](/filings/0001628280-25-046273.md) | not reported | [0.28](/filings/0001628280-26-031287.md) | [0.08](/filings/0001628280-26-053373.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [471](/filings/0001628280-24-004094.md) | [495](/filings/0001628280-25-003748.md) | [527](/filings/0001628280-26-005044.md) | [568](/filings/0001628280-26-005044.md) | [604](/filings/0001628280-26-005044.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [107.3%](/filings/0001628280-24-004094.md) | [101.1%](/filings/0001628280-25-003748.md) | [58.0%](/filings/0001628280-26-005044.md) | [42.8%](/filings/0001628280-26-005044.md) | [11.8%](/filings/0001628280-26-005044.md) |
| Diluted EPS | $ per share | [0.93](/filings/0001628280-24-004094.md) | [0.92](/filings/0001628280-25-003748.md) | [0.56](/filings/0001628280-26-005044.md) | [0.36](/filings/0001628280-26-005044.md) | [0.10](/filings/0001628280-26-005044.md) |
| Free cash flow | $m | [35.5](/filings/0001628280-24-004094.md) | [(61.7)](/filings/0001628280-25-003748.md) | [182](/filings/0001628280-26-005044.md) | [334](/filings/0001628280-26-005044.md) | [357](/filings/0001628280-26-005044.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/doc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.52bn | 70,935,046 |  | Reduced −2,425,473 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.25bn | 58,375,816 |  | Added +249,917 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $963.3m | 45,014,755 |  | Reduced −204,172 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $941.8m | 44,007,417 |  | Reduced −4,493,183 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $661.0m | 30,192,317 |  | Reduced −14,539,224 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $623.2m | 29,119,832 |  | Reduced −81,752 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $526.9m | 24,653,617 |  | Added +252,731 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $396.1m | 18,507,997 |  | Reduced −5,659,477 |
| [PRINCIPAL FINANCIAL GROUP INC](/funds/1126328.md) | 2026-06-30 | $358.7m | 16,760,575 |  | Reduced −2,005,068 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $326.0m | 15,234,655 |  | Reduced −221,765 |

## Recent filings

[All 1,669 filings](/companies/doc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:16 ET | [10-Q](/filings/0001628280-26-053373.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053373 |
| 2026-08-04 | 16:19 ET | [8-K](/filings/0001628280-26-052608.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-052608 |
| 2026-05-06 | 16:16 ET | [10-Q](/filings/0001628280-26-031287.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031287 |
| 2026-05-05 | 16:16 ET | [8-K](/filings/0001628280-26-030561.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-030561 |
| 2026-05-04 | 16:30 ET | [8-K](/filings/0000765880-26-000002.md) | 5.07 Shareholder vote results | 0000765880-26-000002 |
| 2026-03-23 | 16:13 ET | [8-K](/filings/0001104659-26-033312.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-033312 |
| 2026-03-12 | 16:28 ET | [DEF 14A](/filings/0001104659-26-027086.md) | Proxy statement, period 2026-04-30 | 0001104659-26-027086 |
| 2026-02-27 | 07:15 ET | [8-K](/filings/0001104659-26-020982.md) | 7.01 Regulation FD disclosure | 0001104659-26-020982 |
| 2026-02-03 | 16:31 ET | [10-K](/filings/0001628280-26-005044.md) | Annual report, period 2025-12-31 | 0001628280-26-005044 |
| 2026-02-02 | 16:18 ET | [8-K](/filings/0001628280-26-004623.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-004623 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-005044.md), filed Feb 3, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c26424b2-3c77-4113-b4d8-f5a32d4a012f)

## About the filer

- CIK: 765880
- Tickers: DOC
- Exchange: NYSE
- SIC code: 6798 Real Estate Investment Trusts
- State of incorporation: MD
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.